234 related articles for article (PubMed ID: 26097571)
1. SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway.
Li XL; Chen XQ; Zhang MN; Chen N; Nie L; Xu M; Gong J; Shen PF; Su ZZ; Weng X; Tan JY; Zhao T; Zeng H; Zhou Q
Int J Clin Exp Pathol; 2015; 8(4):3871-81. PubMed ID: 26097571
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
3. The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma.
Sun G; Zhang X; Liu Z; Zhu S; Shen P; Zhang H; Zhang M; Chen N; Zhao J; Chen J; Liu J; Dai J; Wang Z; Zhu X; Wang Y; Zeng H
Neoplasia; 2019 Sep; 21(9):921-931. PubMed ID: 31401413
[TBL] [Abstract][Full Text] [Related]
4. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
5. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
6. [Expression of MEK/ERK signal pathways in renal cell carcinoma with bone metastasis].
Qin CP; Liu CL; Zhao YH; Yin HQ; DU YQ; Hu FZ; Sheng ZZ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):590-593. PubMed ID: 29263494
[TBL] [Abstract][Full Text] [Related]
7. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Bridgeman VL; Wan E; Foo S; Nathan MR; Welti JC; Frentzas S; Vermeulen PB; Preece N; Springer CJ; Powles T; Nathan PD; Larkin J; Gore M; Vasudev NS; Reynolds AR
Mol Cancer Ther; 2016 Jan; 15(1):172-83. PubMed ID: 26487278
[TBL] [Abstract][Full Text] [Related]
9. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
10. Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.
Wan YP; Xi M; He HC; Wan S; Hua W; Zen ZC; Liu YL; Zhou YL; Mo RJ; Zhuo YJ; Luo HW; Jiang FN; Zhong WD
Oncol Res Treat; 2017; 40(1-2):15-20. PubMed ID: 28118628
[TBL] [Abstract][Full Text] [Related]
11. RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma.
Zhang Y; Jiang X; Qin X; Ye D; Yi Z; Liu M; Bai O; Liu W; Xie X; Wang Z; Fang J; Chen Y
Oncogene; 2010 Sep; 29(39):5404-15. PubMed ID: 20603618
[TBL] [Abstract][Full Text] [Related]
12. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options.
Brown RE; Buryanek J; Tammisetti VS; McGuire MF; Csencsits-Smith K
Oncotarget; 2016 Jul; 7(27):41612-41621. PubMed ID: 27223432
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells.
Zhang P; Xing Z; Li X; Song Y; Zhao J; Xiao Y; Xing Y
Int J Oncol; 2016 Apr; 48(4):1417-25. PubMed ID: 26820170
[TBL] [Abstract][Full Text] [Related]
14. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.
Haake SM; Li J; Bai Y; Kinose F; Fang B; Welsh EA; Zent R; Dhillon J; Pow-Sang JM; Chen YA; Koomen JM; Rathmell WK; Fishman M; Haura EB
Clin Cancer Res; 2016 Nov; 22(22):5605-5616. PubMed ID: 27220961
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
18. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
19. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
Zhang L; Xie D; Lei Y; Na A; Zhu L
Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
[No Abstract] [Full Text] [Related]
20. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
